

REMARKS

In response to the Restriction Requirement dated August 6, 2010, the Applicants hereby elect Group I. In the Restriction Requirement, the Examiner had required election between the use of an 11- β -HSD-type 1 and/or type 2 inhibitor or a pharmaceutically acceptable salt thereof **for the manufacture of a pharmaceutical agent** and the use of an 11- β -HSD-type 1 and/or type 2 inhibitor or a pharmaceutically acceptable salt thereof **for the prevention and/or treatment of inflammation-induced and/or immune-mediated loss of bone and/or cartilage**, effectively requiring election between a pharmaceutical composition and a method of treatment, as well as election of a set of inhibitors from the 11- β -HSD-type 1 and/or type 2 inhibitors listed in claims 33, 35, 37-45 in Group I and those inhibitors listed in claim 34 and 36, in Groups III and V, respectively. Claims 28-45 have been amended to recast the non-statutory “use” claims as composition and method of treatment claims and to correct typographical errors. Accordingly, claims 32, 33, 35, 37, 38, and 43-45 are presently drawn to a composition comprising the 11- β -HSD-type 1 and/or type 2 inhibitor of Group I. New claim 46 has been added to recite subject matter deleted from claims 28 and 31. No new matter has been added.

Applicants respectfully request that the method of treatment claims (28-31 and 39-42), which depend from claim 45, be rejoined with Group I because the subject matter encompassed by these claims falls under the category of a product and a process of use of said product.

Interview Summary

On September 1, 2010, Applicants' representative contacted the Examiner to inquire about the election requirement. While the Office Action dated August 6, 2010 required an election of species from compounds of formula 1-31, other inhibitor compounds were also recited in claims 32, 43, and 44. The Examiner suggested incorporating these other compounds into claim 33 and electing a single compound from the combined list of compounds. Claims 32, 33, 43, and 44 have been amended accordingly.

Response to Election Requirement

With regard to the requirement to elect a single compound and a single disease, based on the September 1, 2010 telephonic Examiner interview summarized above, Applicants hereby elect glycyrrhetic acid as the compound and periodontitis as the disease. Claims 28-31, 33, 39-42, 45, and 46 read on the elected species.

Respectfully submitted,

By /Robert B. Murray/
Robert B. Murray
Attorney for Applicant
Registration No. 22,980
ROTHWELL, FIGG, ERNST & MANBECK
1425 K. Street, Suite 800
Washington, D.C. 20005
Telephone: (202) 783-6040

RBM/AHH
1768039